At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Florida based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Sr. Vice President & Chief Financial Officer of OPKO Health
Mr. Logal has served as OPKO’s Sr. Vice President and Chief Financial Officer since April 2014 and as OPKO’s Vice President of Finance, Chief Accounting Officer and Treasurer since March 2007. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company.
Follow Adam Logal:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
CFO of Aldevron
Marc Wolff joined us in January 2015 as our Executive Vice President and Chief Financial Officer. He has more than sixteen years of experience in the life sciences industry in various global finance leadership and general management roles. Prior to joining us, from October 2013 to June 2014, Mr. Wolff served as Chief Financial Officer of JHP Pharmaceuticals, LLC, or JHP, a fully integrated specialty pharmaceutical company that acquires, develops, manufactures and sells branded and generic sterile products. He left JHP following the successful completion of the merger with Par Pharmaceutical. Prior to then, from June 2013 to September 2013, Mr. Wolff served as Chief Financial Officer of Research Pharmaceutical Services, Inc. (RPS) a leading provider of disruptive and innovative outsourcing clinical development solutions present in over 60 countries worldwide. In this role, Mr. Wolff directed all financial, tax and treasury aspects of the business including accounting practices, budgeting, financial planning, financing, interface with the financial community, financial analysis, acquisitions and ventures, and monitoring financial, tax and treasury performance. He left RPS following the successful completion of the merger with PRA International. Prior to RPS, Mr. Wolff spent over fifteen years with Catalent Pharma Solutions, a global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products, where he held various global finance leadership and general management roles. In his last position at Catalent Pharma Solutions, Mr. Wolff served as Vice President Finance for the Softgel Technologies division, and Vice President and General Manager Softgel Technologies for Asia Pacific. Mr. Wolff also worked in public accounting from 1993 to 1998 at Arthur Andersen in France. He earned a Master in Management from Ecole Supérieure de Commerce de Reims, France in 1992.
Follow Marc Wolff:
About Aldevron, Sancilio and Company: Aldevron is a biological development and manufacturing organization specializing in cell and genetic engineering.
President, Chief Executive Officer and Chief Financial Officer of Nanotherapeutics
Mr. Matthew joined the Nanotherapeutics Board of Directors in February 2008 and became the Chief Financial Officer of the Company in March 2011. Mr. Matthew is a member of the Board of Managers of NANO ADM, LLC, a wholly-owned subsidiary of the Company. He became President and Chief Executive Officer in May 2016. Mr. Matthew has over 30 years of financial experience, including more than 10 years as the Chief Financial Officer of public and private companies with responsibilities for accounting, finance, information management, investor relations, procurement and facility services. In addition, he has 20 years of experience with KPMG where he was responsible for a variety of transactions and financings for the Health Care and Life Sciences Industry Group. Mr. Matthew received an MBA from Michigan State University and a B.S. in Accountancy from the University of Illinois at Springfield.
Follow James Matthew:
About Nanotherapeutics: Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities,
Chief Financial Officer of Tissuetech
Michael Cornelius joined TissueTech as Chief Financial Officer in 2014 with more than 25 years of experience in public accounting and public and private corporations. Michael Cornelius was previously with Stiefel Laboratories, serving as its Chief Financial Officer. Stiefel Laboratories was the largest privately-held dermatology company in the world, before it was acquired by GlaxoSmithKline in 2009. Mike began his career with the international accounting and consulting firm, Grant Thornton, where he specialized in US and International tax planning and also held senior level finance positions with IVAX Corporation and Sunglass Hut International. Mike holds a Bachelor of Science in Business Administration from Indiana University of Pennsylvania and is a Certified Public Accountant.
Follow Michael Cornelius:
About Tissuetech: Tissuetech offers regenerative amniotic tissue-based products for ophthalmology, optometry, musculoskeletal, and wound care markets.
Chief Financial Officer of Longeveron
James Clavijo is the Chief Financial Officer at Longeveron.
Follow James Clavijo:
About Longeveron: Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases.
CFO of Vigilant Biosciences
Robert T. Hamilton currently serves as the company’s CFO. Hamilton, a former Big-Four CPA with 15+ years of public co. and venture-backed private portfolio company experience, has worked with companies in e-commerce, health and fitness, technology and retail/wholesale industries. Prior to Vigilant Biosciences, Hamilton served as CFO of Bridgevine, Inc., a privately held and venture-backed, e-commerce solution that assists Fortune 500 marketers and advertisers with new customer acquisition through a closed-loop platform. He helped Bridgevine complete a financial turnaround and grow revenues profitably to $50+MM. Previously, as CFO of eDiets, Inc. (formerly NASDAQ- DIET), a leading provider of online weight loss solutions serving over 2 million paying clients, he successfully oversaw its B2C and B2B revenues grow 25 times in a profitable manner and led the company’s transition from a self-funded private company to a NASDAQ listing. Hamilton began his career as an auditor with Arthur Andersen, LLP in Boston. Progressing to audit manager, he serviced multinational SEC and non-public clients in the high technology, manufacturing, retail/wholesale distribution, and hospitality industries. Hamilton is a Certified Public Accountant and received his Bachelors in Business Administration from Merrimack College.
Follow Robert Hamilton:
About Vigilant Biosciences: Vigilant Biosciences is a innovator and developer of solutions that aid in the early detection and intervention of cancer.